

OPTIMIZING DRUG THERAPY WITH PERSONALISED DOSING

MyFID® is the first smart dosing device for tablets, combining modern smart phone technology and "micro" - tablets to achieve improved and better usage of medicines



www.sensidose.se

SALSS CONTACT

Jack Spira
CEO

jack.spira@sensidose.se
+46 (0)10-707 73 80

Sensidose AB
Vetenskapsvägen 10
191 38 Sollentuna
Sweden



Sensidose AB is a commercial phase company with a unique and patented system for personalized and optimized drug therapy. Its Flexilev® (levodopa/carbidopa) microtablets, for the treatment of Parkinson's disease, are reimbursed in Sweden, with marketing authorisation granted in a further 13 European countries.

OUR PRODUCTS & SERVICES

MyFID® is a patented system comprising an automated dispensing unit and "micro"-tablets, sub-pharmaceutical units of tablets. The correct dose is achieved by dosing a certain number of tablets. The dispenser has an inbuilt alarm, delivers doses at the programmed time point, and registers all doses delivered as well as disease symptoms, with the help of easy to use scales.

MyFID is pre-programmed to deliver a certain amount of medicine at a certain time. The physician decides which dose a patient should use and when it should be taken. A built-in log function registers all doses and disease symptoms, allowing the physician and patients to gradually adjust the optimal and customized dosing.

Two clinical Phase I studies have been carried out. The first demonstrated bioequivalence of Flexilev®, Sensidose's own product and Sinemet®, within acceptance level. The second showed that Flexilev gave more steady concentrations than Stalevo®, faster absorption and shorter time to maximum plasma concentration.

MyFID is ordered direct from Sensidose, while micro-tablets are collected from the pharmacy as usual, upon instruction from a prescribing physician.

WHAT MAKES US UNIQUE

MyFID is unique in providing specificity of dosing – patients can adjust their dose in steps of 5 mg, hence they do not need to take 100 mg or 200 mg, for example, but can choose 120, 125 or 130 mg, to suit their precise need. Our systems enable patients and doctors to find the correct dose, and encourage patients to adhere to treatment.

WHY YOU SHOULD MEET US

Sensidose is looking to further commercialise and expand the use of its flagship product through international distribution agreements in countries where it has marketing authorisation. The Company is also looking for further investment support to advance international sales and market development.

KEY TEAM

Jack Spira MD, PhD

- CEO
- 25+ years pharmaceutical industry experience mainly in Pharmacia but also in leading positions in several global pharmaceutical companies

Pontus Salomonson

- Head of Sales & Marketing
- Formerly Head of Parkinson's, Nordics, Grünenthal Group and Global Brand Manager, Lundbeck

Alf Malmberg, PhD

- Head of QA
- 30 years medical device business experience
- QA & RA Manager at Carmeda AB
- Senior QA&RA Consultant, designing and implementing quality systems and technical files for small and medium sized companies.

